Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers

NCT04160065 is registered in ClinicalTrials.gov with TuHURA Biosciences, Inc. as lead sponsor.

NCT NCT04160065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04160065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers
Lead sponsor
TuHURA Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 3, 2020
Completion date
August 13, 2024
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma, merkel cell carcinoma, non-melanoma skin cancers